Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's …
Industry Peers
Drug Manufacturers - Specialty & Generic| Headline | Source | Time |
|---|---|---|
Older | ||
 ESPR Stock Surges 44% in a Month: Here's What You Need to Know Esperion shares jump nearly 44% in a month. The primary catalyst was Archimed's agreement to acquire the company in a deal valued at up to $1.1 billion, including milestone payments. | ||
 ARCHIMED to acquire Esperion Therapeutics in $1.1 billion deal Shareholders will receive $3.16 per share in cash at closing — a 58% premium — plus contingent payments of up to $100 million | ||
 Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast cancer medicine. | ||
 Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference Esperion Therapeutics (NASDAQ:ESPR) outlined its commercial progress and strategic priorities at Needham & Company’s 25th Annual Healthcare Conference, highlighting revenue growth, new clinical and guideline tailwinds for its cholesterol franchise, and the recent acquisition of Corstasis Therape | ||
 Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound? Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | ||
 Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar? Karyopharm Therapeutics (KPTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. | ||